Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
34.20 USD   -2.51%
09/29Zai Lab's H1 Loss Narrows to $220 Million; Shares Slip 6%
MT
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK (tisotumab vedotin-tftv)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

07/19/2022 | 07:39am EDT

Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ET

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended June 30, 2022, after the closing of the U.S. equity markets on August 9, 2022. The Company will host a live conference call and webcast on August 10, 2022, at 8:00 a.m. ET.

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows:

Registration Link: https://register.vevent.com/register/BI462e47de1af64af599432ab5c90a148b

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://ir.zailaboratory.com.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

Investor Relations: Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Source: Zai Lab Limited


All news about ZAI LAB LIMITED
09/29Zai Lab's H1 Loss Narrows to $220 Million; Shares Slip 6%
MT
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Zai Lab Strikes Licensing Deal with Nasdaq-listed Seagen for Cervical Cancer Drug
MT
09/27Zai Lab Signs Exclusive Collaboration, License Agreement With Seagen to Develop, Commer..
MT
09/27Zai Lab : Corporate Presentation
PU
09/27Zai Lab Ltd : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financ..
AQ
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
GL
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
CI
09/21Asian ADRs Move Lower in Wednesday Trading
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 221 M - -
Net income 2022 -468 M - -
Net cash 2022 796 M - -
P/E ratio 2022 -7,61x
Yield 2022 -
Capitalization 3 278 M 3 278 M -
EV / Sales 2022 11,2x
EV / Sales 2023 5,64x
Nbr of Employees 1 951
Free-Float 99,8%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 34,20 $
Average target price 93,57 $
Spread / Average Target 174%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Joshua L. Smiley Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-45.58%3 278
CSL LIMITED-1.96%88 546
SAMSUNG BIOLOGICS CO.,LTD.-10.63%39 998
BIOGEN INC.11.29%38 745
WUXI BIOLOGICS (CAYMAN) INC.-48.78%25 758
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 438